SOLICITATION NOTICE
R -- National Coordinating Center for the Prevention and Treatment of Sickle Cell Disease
- Notice Date
- 4/14/2006
- Notice Type
- Solicitation Notice
- NAICS
- 541611
— Administrative Management and General Management Consulting Services
- Contracting Office
- Department of Health and Human Services, Health Resources and Services Administration, Division of Procurement Management, 5600 Fishers Lane, Room 13A-19, Rockville, MD, 20857
- ZIP Code
- 20857
- Solicitation Number
- RFP06N2405508DP
- Response Due
- 6/15/2006
- Archive Date
- 6/30/2006
- Description
- The Health Resources and Services Administration (HRSA) is soliciting proposals from organizations to provide a National Coordinating Center for the Demonstration Program for the Development and Establishment of Systemic Mechanics for the Prevention and Treatment of Sickle Cell Disease. This is a Full and Open Competitive Requirement. The contractor shall establish a Sickle Cell Disease National Coordinating Center that will coordinate the activities of four grant entities funded under the demonstration program for the Division of Services for Children with Special Health Heads, Maternal Child Health Bureau (MCHB), HRSA. The NAICS Code is 541611 with a small business standard of 6.0 million. The Federal Maternal and Child Health Bureau (MCHB) has a long recognized the significance of sickle cell disease. In the mid 1960s, MCH developed and disseminated sickle cell disease educational materials nationally. Following passage of the National Sickle Cell Anemia Control Act in 1972, MCH, with initial funding from the National Institutes of Health (NIH), provided support for community based sickle cell clinics to conduct testing, counseling, and education. In the mid 1980s, the Federal MCHB supported the development and implementation of State newborn screening programs for sickle cell disease. By 1990, 30 States and jurisdictions had implemented programs with direct Federal support. Currently all States mandate universal screening as recommended by the 1987 Consensus Development Conference on Newborn Screening for Sickle Cell and Other Hemoglobinopathies. In 2002, MCHB funded 15 community-based grants and one cooperative agreement through its Sickle Cell Disease and Newborn Screening Program. In 2004, Congress enacted and the President signed into law P.L. 103-357. Section 712 of P.L. 103-357 authorized the Sickle Cell Disease (SCD) Treatment Demonstration Program. Its purpose is to develop and establish systemic mechanisms to enhance the prevention and treatment of sickle cell disease. HRSA will carry out the legislation through the support of a National Coordinating Center and Regional SCD Treatment Demonstration Collaboratives (Regional Collaboratives). Each Regional Collaborative will support the work of five to 10 individual community-based treatment demonstration programs. The community-based programs will facilitate the delivery of education, health promotion, patient and family support, state-of-the-art treatment, and continuous, coordinated care to individuals with SCD. These programs also will develop collaborative agreements with: (a) a community-based SCD organization or nonprofit entity that works with individuals with SCD; (b) the SCD newborn screening program for the State in which it is located; (c) the Title V Maternal and Child Health program for the State; (d) the HRSA Regional Genetic and Newborn Screening Collaborative in its area; and (e) other partners. The scope of work requires the National Coordinating Center to (i) collect, coordinate, monitor, and distribute data, best practices, and findings regarding the activities of the Regional Collaborative; (ii) develop a model protocol for eligible entities with respect to the prevention and treatment of SCD; (iii) develop educational materials regarding the prevention and treatment of SCD; and (iv) prepare and submit to Congress a final report that includes recommendations regarding the effectiveness of the Regional Collaborative and such direct outcome measures as--(I) the number and type of health care resources utilized (such as emergency room visits, hospital visits, length of stay, and physician visits for individuals with SCD; and (II) the number of individuals that were tested and subsequently received genetic counseling for the sickle cell trait. The development and establishment of systemic mechanisms to improve the prevention and treatment of SCD requires extensive knowledge and expertise in the system of care that serves people with SCD and the SCD Community as a whole. This includes extensive knowledge and expertise in genetic counseling and testing; bundling of technical services related to the prevention and treatment of SCD; training of health professionals; treatment (including SCD treatment centers); continuity of care programs; consumer education; community-based SCD organizations or nonprofit entities that work with individuals who have SCD; SCD newborn screening programs and the maternal and child health programs under Title V of the Social Security Act (42 U.S.C. 701 et seq.) The contractor shall demonstrate familiarity with Federally-qualified health centers, reimbursement under the Medicaid program, State children?s health insurance program, and other health programs for the prevention and treatment of SCD. This requirement is to be constructed as a three phase contract over four years. This base year of the contract shall target on Program Planning, Program Implementation of Projects with Projects? Evaluations, and Program Outcome Evaluation. In addition to serving as a coordinating center for the demonstration program, the legislation indicates the Sickle Cell Disease National Coordinating Center shall: (1) Collect, coordinate, monitor, and distribute data, best practices, and findings regarding the activities funded under grants (the Networks) made to eligible entities under the demonstration program; (2) Develop a model protocol for eligible entities with respect to the prevention and treatment of Sickle Cell Disease; (3) Develop educational materials regarding the prevention and treatment of sickle cell disease; and (4) Prepare and submit to Congress a final report that includes recommendations regarding the effectiveness of the demonstration program conducted under this subsection and such direct outcome measures as the number and type of health care resources utilized (such as emergency room visits, hospital visits, length of stay, and physician visits for individuals with Sickle Cell Disease); and the number of individuals that were tested and subsequently received genetic counseling for the sickle cell trait. The anticipated evaluation criteria include: (1) Statement of Understanding of the Project Purpose (2) The Technical Approach to Task (3) Personnel (4) Management Plan and (5) Organizational Experience and Expertise. The Government anticipates award of a contract consisting of a twelve month base period and three (3) option years... This is a pre-solicitation notice and not a request for proposals. The solicitation document (RFP) will be posted at this site www.fedbizopps.gov within thirty (30) days of this notice and can be downloaded by looking under the main menu for HHS/Office-Health Resources and Services Administration/locations-Division of Procurement Management. The closing date for receipt of proposals will be approximately thirty (30) days after issuance/posting of the RFP. It shall be the offeror?s responsibility to monitor this website for the RFP and any amendments to the RFP. The agency will consider proposals from all responsible sources. The contact person for this acquisition is: Debora A. Pitts, Contracts Operations Branch, DPM/OMPS/HRSA, Parklawn Building, 5600 Fishers Lane, Room 13A-19, Rockville, MD 20857-5600; phone number 301-443-3789 or 443-2750; FAX 301-443-6038.
- Place of Performance
- Address: Rockville,MD
- Zip Code: 20852
- Zip Code: 20852
- Record
- SN01028234-W 20060416/060414220439 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |